3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Docetaxel
7
pembrolizumab
3
Trastuzumab
3
Radiotherapy
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Cisplatin
3
Vorinostat
2
Taxes
2
SS1(dsFv)PE38
2
Polymerase Chain Reaction
2
Magnetic Resonance Spectroscopy
2
Immunohistochemistry
2
Gene Expression Profiling
2
Filgrastim
2
Cetuximab
2
Biopsy
2
zanidatamab
1
vandetanib
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
talactoferrin alfa
1
spartalizumab
1
sargramostim
1
pertuzumab
1
neratinib
1
larotrectinib
1
fluoromisonidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
larotrectinib
×
Thoracic
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA